Log in with your email address username.


[Correspondence] New development of medicines for priority diseases in Africa

Infectious diseases disproportionately affect low-income and middle-income countries, yet many do not have optimal therapies or vaccines,1,2 as underscored by the west African Ebola virus outbreak.3 Product developers are increasingly focusing on Africa and countries with high disease burden. However, regulatory processes and systems in many African countries are weak and unclear.4,5 For these reasons, in 2006 WHO established the African Vaccine Regulatory Forum (AVAREF) to build capacity of regulatory and ethics agencies, and improve harmonisation of practices in support of product development.